The New England Journal of Medicine Publishes Data from Phase 2b Trial of Oral Orexin Receptor 2 Agonist Oveporexton (TAK-861) in People with Narcolepsy Type 1
Development of a narcolepsy patient-reported outcome measure and assessment of its psychometric properties
Future Neurology “Effects of oxybate dose and regimen on disrupted nighttime sleep and sleep architecture: A Plain Language Summary”
